BioCentury | Oct 2, 2020

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to treat pediatric steroid-refractory acute GvHD. FDA’s Oncologic Drugs Advisory Committee had voted 9...
BioCentury | Mar 25, 2019
Distillery Techniques

Stem cell-derived 3-D microvessel grafts for heart damage in cardiovascular diseases

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Cell therapy Rat studies suggest grafts based on a hESC-derived endothelial cell microvessel construct could help treat heart damage caused by cardiovascular diseases. Generation of the grafts involves seeding hESC-derived...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Sep 20, 2018
Distillery Therapeutics


INDICATION: Hearing loss Mouse studies suggest inhibiting DDIT3 or PERK could help treat hearing loss. In a mouse model of genetic hearing loss, systemic knockout of DDIT3 decreased hearing loss compared with normal DDIT3 expression....
BioCentury | Mar 15, 2017
Distillery Therapeutics


INDICATION: Cardiomyopathy Patient sample and mouse studies suggest inhibiting DDIT4L could help treat pathological cardiomyopathy. In left ventricular tissue samples from patients with dilative cardiomyopathy (DCM), levels of DDIT4L were higher than in samples from...
BioCentury | Jun 5, 2014
Targets & Mechanisms

De-stressing glaucoma

Glucocorticoids are standard of care for a host of allergic and inflammatory eye conditions, but they elevate intraocular pressure about a third of the time and can result in secondary open-angle glaucoma. A chemical chaperone...
BioCentury | May 15, 2014
Distillery Therapeutics

Indication: Neurology

...and contact information Neurology Depression DNA-damage-inducible transcript 4 (DDIT4; RTP801; REDD1) Rodent and human studies suggest inhibiting REDD1...
...1 (mTORC1) inhibitor REDD1 was increased compared with that in samples from individuals without MDD. Redd1...
...REDD1. Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. and Pfizer Inc. have PF-655, an siRNA targeting REDD1...
BioCentury | May 7, 2012
Company News

Quark, Pfizer deal

...assumes development of PF-655 for OAG. The short interfering RNA that inhibits the expression of RTP801...
BioCentury | Feb 23, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology DNA-damage-inducible transcript 3 (DDIT3; CHOP10; CHOP; GADD153); x-box binding protein 1 (XBP1) Mouse studies suggest inhibiting CHOP or activating XBP1 could help treat neurodegenerative...
BioCentury | Sep 28, 2011
Financial News

Quark pulls IPO

...PF-655 ( PF-04523655 ), an siRNA that inhibits the expression of DNA-damage-inducible transcript 4 ( DDIT4 ; RTP801...
Items per page:
1 - 10 of 51